Leap Therapeutics, Inc. (LPTX) |
|
1.38 -0.02 (-1.43%)
|
09-29 16:00 |
|
Open: |
1.45 |
Pre. Close: |
1.4 |
|
High:
|
1.45 |
Low:
|
1.35 |
|
Volume:
|
119,548 |
Market Cap:
|
35(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:28:49 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.32 One year: 2.83 |
| Support: |
Support1: 1.26 Support2: 1.05 |
| Resistance: |
Resistance1: 1.98 Resistance2: 2.43 |
| Pivot: |
1.5  |
| Moving Average: |
MA(5): 1.37  MA(20): 1.64
MA(100): 3.66 MA(250): 4.81 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 16.5 %D(3): 13.3 |
| RSI: |
RSI(14): 28.1 |
| 52-week: |
High: 10.19 Low: 1.26 |
| Average Vol(K): |
3-Month: 253 (K) 10-Days: 134 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LPTX ] has closed above bottom band by 32.5%. Bollinger Bands are 70% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 55 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.45 - 1.46 |
1.46 - 1.47 |
|
Low:
|
1.33 - 1.34 |
1.34 - 1.35 |
|
Close:
|
1.37 - 1.38 |
1.38 - 1.39 |
|
Company Description |
|
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. |
Headline News |
Tue, 05 Sep 2023
Leap Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance
Wed, 16 Aug 2023
Is it Time to Dump Leap Therapeutics Inc (LPTX) Stock After it Has Risen 7.62% in a Week? - InvestorsObserver
Wed, 12 Jul 2023
Leap Therapeutics Announces Initiation of Randomized Controlled ... - PR Newswire
Tue, 20 Jun 2023
Leap Therapeutics Announces Reverse Stock Split - PR Newswire
Thu, 25 May 2023
Leap Therapeutics to Present Updated Data from Part A of the ... - PR Newswire
Mon, 15 May 2023
Leap Therapeutics Reports First Quarter 2023 Financial Results - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
26 (M) |
| Shares Float |
25 (M) |
|
% Held by Insiders
|
3.8 (%) |
|
% Held by Institutions
|
23.3 (%) |
|
Shares Short
|
672 (K) |
|
Shares Short P.Month
|
733 (K) |
Stock Financials |
|
EPS
|
-5.99 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.28 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-55.7 |
|
Return on Equity (ttm)
|
-98.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.31 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-48 (M) |
|
Levered Free Cash Flow
|
-49 (M) |
Stock Valuations |
|
PE Ratio
|
-0.24 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
0.41 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.74 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
